A favorable HHS-OIG advisory opinion could accelerate interest in multi-cancer early detection (MCED) testing by allowing a company to provide a free supplemental multi-cancer risk report alongside a Medicare-covered colorectal cancer blood test.
While regulators acknowledged the arrangement could raise anti-kickback concerns, they concluded the risk was low because the additional analysis uses the same blood sample, creates no extra cost to Medicare, and may provide clinically meaningful information for cancers that currently lack established screening options. The decision highlights growing regulatory openness to innovative cancer screening approaches while maintaining safeguards against inappropriate utilization and patient steering.